A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
Clinical trial NCT00730379 · COMPLETED
Trial details
- NCT number
- NCT00730379
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2008-07-01
- Primary completion
- 2010-11-01
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.